Clinical trials: Relapsing Remitting Multiple Sclerosis RRMS
Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS)
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors.
- Trial name
- NCT01233245
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 15 sites in Czechia, France and 13 more
- Volunteers
- 1,077 people
- Sponsor
- Bayer
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
Extension Study of MT-1303
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT01890655
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 17 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 367 people
- Sponsor
- Tanabe Pharma Corporation
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
The primary objective of this study is to estimate the incidence of Anti-Natalizumab Antibodies (ANAs) in the cohort of natalizumab-naïve and other MS monoclonal antibody (mAb)-naive participants who start receiving natalizumab…
- Trial name
- NCT05925049
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis (RRMS)
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage.
- Trial name
- TWINS (NCT06663189)
- Testing
- treatment withdrawal, Usual DMT continuation, MRI
- Where
- 22 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Relapsing Remitting Multiple Sclerosis
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects.
- Trial name
- Estriol-MS (NCT00451204)
- Testing
- Estriol, Copaxone
- Where
- 16 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis, Relapsing-Remitting
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies.
- Trial name
- TOTEM-RRMS (NCT03910738)
- Testing
- Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, MRI, Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population…
- Trial name
- GASWI (NCT01695434)
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive…
- Trial name
- ADHERENCE (NCT03408093)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Volunteers
- 120 people
- Sponsor
- Bayer
Multiple Sclerosis
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication.
- Trial name
- RAM-MS (NCT03477500)
- Testing
- Cyclophosphamide and ATG, Alemtuzumab, Cladribine Pill
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone…
- Trial name
- CONFIDENCE (NCT02499900)
- Testing
- Copaxone®
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 861 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Neurogenic Bladder
Vaginal Estriol in Multiple Sclerosis
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS…
- Trial name
- NCT03774407
- Testing
- vaginal estriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Texas Tech University Health Sciences Center
Relapsing Remitting Multiple Sclerosis
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®
- Trial name
- NCT00202995
- Testing
- Glatiramer Acetate, Betaseron, Rebif
- Volunteers
- 91 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
- Trial name
- FILYRA (NCT06949956)
- Volunteers
- 140 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis, Relapsing-Remitting
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
- Trial name
- NCT02555215
- Testing
- dimethyl fumarate
- Where
- 12 sites in United States, Belgium and 8 more
- Volunteers
- 20 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.
- Trial name
- INSPIRE (NCT01767701)
- Testing
- Raltegravir
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Queen Mary University of London